Does Wegovy Help Burn Fat, or Is the Weight Loss More Complicated Than That?

Does Wegovy actually burn fat, or does it just reduce appetite?

The honest answer is both, but not in the way most people picture. Wegovy doesn't act on fat cells directly. What semaglutide does is mimic GLP-1, a hormone released after eating, which signals the brain to reduce hunger and the stomach to slow its emptying. You feel full on less food, eat less over the day, and that gap between what you consume and what your body needs gets filled by stored energy, predominantly body fat.

So fat is burned, but as a downstream consequence of reduced intake, and if you want to understand exactly how semaglutide burns fat at a mechanistic level, the picture is more nuanced than a simple yes or no. The distinction matters because it shapes expectations: Wegovy won't strip fat quickly or preferentially from any particular area. What it does, reliably, is make eating less feel manageable rather than miserable, and that consistency over months is what produces meaningful changes in body composition.

For a fuller look at the mechanisms involved, the full explanation of how Wegovy works covers the GLP-1 pathway in more detail. The NHS semaglutide medicines page also sets out clearly what the medicine does and what its common effects are.

What does the evidence say about fat loss specifically, not just total weight?

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity or overweight over 68 weeks. Participants taking semaglutide 2.4mg lost an average of around 15% of their body weight compared with about 2.4% in the placebo group. Body composition analyses from the STEP programme found that the majority of weight lost was fat mass, with visceral fat (the metabolically active fat stored around internal organs) showing particularly significant reductions.

That said, lean mass does decline to some degree during any substantial weight-loss period. The body doesn't shed fat in isolation. Whether that muscle loss is clinically meaningful depends on how well someone maintains protein intake, stays active and preserves strength during treatment. Our detailed page on semaglutide, fat and muscle loss unpacks this question specifically, including what the research says about preserving lean tissue.

The short version: Wegovy produces predominantly fat loss, but it's worth thinking about muscle preservation from day one rather than treating it as an afterthought.

Does Wegovy specifically reduce belly fat?

This question comes up a lot, and the evidence is encouraging. Visceral fat (the fat that accumulates deep in the abdominal cavity, around organs like the liver and pancreas) is strongly associated with cardiovascular risk and metabolic disease. STEP programme data showed that semaglutide reduced visceral fat more than would be expected from the total weight loss alone, suggesting the GLP-1 pathway may influence where the body preferentially loses fat, at least to some extent.

Subcutaneous fat (the kind you can pinch) also reduces, though it tends to respond more slowly. There's no reliable evidence that semaglutide targets one body area over another in a precise or controllable way, overall calorie deficit remains the primary driver. For anyone specifically curious about this, our page on Wegovy and belly fat covers the trial data on abdominal measurements in more depth.

It's also worth noting that context shapes results significantly. Protein adequacy, sleep, stress management and movement all influence whether a calorie deficit comes predominantly from fat or from a less favourable mix. A prescriber can help you think through the lifestyle piece alongside treatment.

Who is licensed to use Wegovy for weight loss in the UK?

Wegovy is licensed for adults aged 18 and over with a BMI of 30 or above, or those with a BMI of 27–29.9 who also have at least one weight-related condition, things like high blood pressure, high cholesterol, obstructive sleep apnoea or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI alone doesn't determine approval; the prescriber reviews your full medical picture, current medicines and any contraindications before deciding.

If cost is part of your thinking, our Wegovy cost page sets out what's included in a single transparent price and what to watch for when comparing providers. And if you're wondering about age, the licensing position for younger adults is covered on our Wegovy minimum age page.

Treatment at nume is private, with no waiting list and no referral needed. Your consultation lands on a real prescriber's desk (not software) and if you're clinically suitable, orders placed before noon on a working day are dispatched the same afternoon. Some people time their first order around payday or a Monday start; the process is the same either way. The only route to these medicines is a prescription following genuine clinical review, and a free consultation with our prescribers is the place to start.